SCHEMBL2118524

SCHEMBL2118524

Cc1ccc(-c2ccco2)cc1NS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 2/20 0.57
ALDH1A1 P00352 2/20 0.56
POLB P06746 1/20 0.56
CYP3A4 P08684 1/20 0.54
MAPT P10636 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
TP53 P04637 2/20 0.50
GHSR Q92847 2/20 0.49
DRD2 P14416 1/20 0.49
HTR2A P28223 1/20 0.49
HTR2C P28335 1/20 0.49
DRD3 P35462 1/20 0.49
HTR6 P50406 1/20 0.49
ALOX15 P16050 1/20 0.48
FFAR4 Q5NUL3 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MEN1 O00255 1/20 0.46
PKM P14618 1/20 0.46
KMT2A Q03164 1/20 0.46
APP P05067 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2119088 0.88 TRIM24 (0.60) TRIM24ALDH1A1POLBCYP3A4SMN1; SMN2
SCHEMBL2120619 0.88 TRIM24 (0.57) TRIM24ALDH1A1POLBCYP3A4MAPT
SCHEMBL2117223 0.85 TRIM24 (0.55) TRIM24ALDH1A1POLBCYP3A4MAPT
SCHEMBL2120627 0.84 TRIM24 (0.59) TRIM24ALDH1A1POLBCYP3A4SMN1; SMN2
SCHEMBL2121409 0.82 TRIM24 (0.55) TRIM24ALDH1A1POLBCYP3A4MAPT
SCHEMBL2118685 0.82 POLB (0.57) ALDH1A1POLBCYP3A4MAPTSMN1; SMN2
SCHEMBL2117458 0.81 POLB (0.54) ALDH1A1POLBMAPTSMN1; SMN2TP53
SCHEMBL2118988 0.81 TRIM24 (0.56) TRIM24ALDH1A1POLBCYP3A4MAPT
SCHEMBL2119450 0.80 TRIM24 (0.52) TRIM24POLBCYP3A4MAPTSMN1; SMN2
SCHEMBL3792512 0.80 TRIM24 (0.57) TRIM24ALDH1A1CYP3A4MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1AN, HIF1A, EGLN2 TRIM24 1787/4885ALDH1A1 567/4885POLB 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.